EUVIMEDEUVIMED entdecken
Crossref

Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer

C S Beduk Esen, M E Gedik, H Canpinar, F Y Yedekci, F Yildiz, G Gunaydin, M Gultekin

Clinical Oncology · 2023

DOI: 10.1016/j.clon.2023.08.007 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Oncology, 2023. Verfasst von C S Beduk Esen und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey. Electronic address: selengebeduk@hacettepe.edu.tr. Hauptthemen laut MEDLINE: Metformin, Uterine Cervical Neoplasms, Lung Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: The role of metformin on the radiosensitising effect of cisplatin is not clear. Here we investigated the radiosensitising effect of metformin alone and combined with cisplatin in HeLa cells, as well as the implications of the adenosine monophosphate-activated protein kinase (AMPK) pathway on the radiosensitising effect. MATERIALS AND METHODS: HeLa cells were treated with ionising radiation, metformin, cisplatin, A769662 (AMPK activator) and dorsomorphin (AMPK inhibitor) or in combination. A cell proliferation assay, Western blot and flow cytometry were carried out. RESULTS: Metformin potentiated cisplatin cytotoxicity when administered 4 h before ionising radiation. Although the radiosensitising effects of metformin and cisplatin alone were observed, which is more apparent at high ionising radiation doses, the metformin-cisplatin combination did not increase the radiosensitivity of cisplatin at any ionising radiation dose. Dorsomorphin alone significantly decreased cell proliferation and potentiated the radiosensitising effects of cisplatin with ionising radiation. Administration of A769662 24 h prior to cisplatin treatment resulted in an increased AMPK level that yielded resistance to cisplatin, but this effect was not observed in HeLa cells concomitantly treated with A769662 and cisplatin. CONCLUSIONS: Modulation of AMPK may have a role in cervical cancer treatment. Increased AMPK levels result in higher sensitivity to ionising radiation but causes resistance to cisplatin. Dorsomorphin is proven to be a potent radiosensitising agent. The use of metformin alone may be an option as a radiosensitiser during high-dose ionising radiation (e.g. intracavitary brachytherapy).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminUterine Cervical NeoplasmsLung NeoplasmsFemaleHumansCisplatinAMP-Activated Protein KinasesHeLa CellsApoptosisChemoradiotherapyCell Line, TumorBiphenyl CompoundsPyronesThiophenes

Stichwörter der Autor:innen

AMPKcervical cancercisplatinionising radiationmetforminradiosensitivity

Substanzen

CisplatinMetforminAMP-Activated Protein Kinases4-hydroxy-3-(4-(2-hydroxyphenyl)phenyl)-6-oxo-7H-thieno(2,3-b)pyridine-5-carbonitrileBiphenyl CompoundsPyronesThiophenes

Autor:innen und Institutionen

  • Department of Radiation Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey. Electronic address: selengebeduk@hacettepe.edu.tr.
  • Department of Basic Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara, Turkey. Electronic address: emregediktr@gmail.com.
  • Department of Basic Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara, Turkey. Electronic address: hcanpinar@gmail.com.
  • Department of Radiation Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey. Electronic address: yagiz.yedekci@hacettepe.edu.tr.
  • Department of Radiation Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey. Electronic address: ferahyildiz66@gmail.com.
  • Department of Radiation Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara, Turkey; Department of Basic Oncology, Hacettepe University Cancer Institute, Sihhiye, Ankara, Turkey. Electronic address: gurca…

Zitieren

APA

Beduk Esen, C. S., Gedik, M. E., Canpinar, H., Yedekci, F. Y., Yildiz, F., Gunaydin, G., & Gultekin, M. (2023). Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer. Clinical Oncology. https://doi.org/10.1016/j.clon.2023.08.007

Vancouver

Beduk Esen CS, Gedik ME, Canpinar H, Yedekci FY, Yildiz F, Gunaydin G, et al. Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer. Clinical Oncology. 2023. doi:10.1016/j.clon.2023.08.007

BibTeX
@article{BedukEsen2023,
  author = {Beduk Esen, C S and Gedik, M E and Canpinar, H and Yedekci, F Y and Yildiz, F and Gunaydin, G and Gultekin, M},
  title = {Radiosensitising Effects of Metformin Added to Concomitant Chemoradiotherapy with Cisplatin in Cervical Cancer},
  journal = {Clinical Oncology},
  year = {2023},
  doi = {10.1016/j.clon.2023.08.007}
}
Kostenlos starten →